<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8 - K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) FEBRUARY 28, 1997
-----------------
GALILEO CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 04-2526583
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
0-11309
(Commission File Number)
GALILEO PARK, P.O. BOX 550, STURBRIDGE, MASSACHUSETTS 01566
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code (508) 347-9191
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
1
<PAGE> 2
Item 2. Acquisition or Disposition of Assets
------------------------------------
On February 28, 1997, the Registrant acquired certain assets of the
Sani-Spec(TM) product line from C. R. Bard, Inc. pursuant to the Asset
Purchase Agreement dated as of February 28, 1997 (the "Purchase
Agreement") between Galileo Corporation and C. R. Bard, Inc. The
purchased assets include manufacturing equipment, molds, inventory and
trademarks.
The Registrant purchased the assets for $5.5 million in cash from
general funds, and the acquisition will be accounted for as a purchase.
The terms of the transaction are more fully set forth in the Purchase
Agreement filed as Exhibit 2.1 hereto. Neither the Registrant nor any of
its affiliates had any relationship with C. R. Bard, Inc. prior to the
transaction.
The Sani-Spec product line which was acquired by the Registrant includes
the Sani-Spec single-use vaginal speculums, the Sani-Scope(TM)
anoscopes, the Spec Light(TM) speculum lights and Pap smear kits. All of
these products are used principally by OB/GYN physicians, clinics and
hospitals and are marketed through a nationwide network of approximately
80 dealers. The Registrant considers the addition of these products and
their related distribution channel to be an integral part of its
continuing strategy to increase its presence in the women's health care
market.
Item 7. Financial Statements and Exhibits
---------------------------------
a) Financial Statements of Business Acquired
Not applicable.
b) Pro Forma Financial Information
Not applicable.
c) Exhibits
2.1 Asset Purchase Agreement, dated February 28, 1997, between
Galileo Corporation and C. R. Bard, Inc. The schedules and
exhibits to the Agreement are omitted and will be furnished to
the Commission upon request.
99.1 Press Release dated March 3, 1997
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GALILEO CORPORATION
Date: March 12, 1997 By: /s/ Josef W. Rokus
--------------------------------------
Josef W. Rokus
Vice President, Corporate Development
and Secretary
3
<PAGE> 4
EXHIBIT INDEX
Exhibit No.
-----------
2.1 Asset Purchase Agreement dated February 28, 1997.
99.1 Press Release dated March 3, 1997
4
<PAGE> 1
Exhibit No. 2.1
=========================================
ASSET PURCHASE AGREEMENT
between
GALILEO CORPORATION
and
C.R. BARD, INC.
-----------------------
February 28, 1997
-----------------------
=========================================
<PAGE> 2
TABLE OF CONTENTS
Page
----
SECTION 1 - SALE AND PURCHASE............................... 1
1.1 Purchased Assets.......................... 1
----------------
1.2 Excluded Assets........................... 2
---------------
1.3 No Assumption of Liabilities.............. 2
----------------------------
1.4 Purchase Price............................ 2
--------------
1.5 Closing................................... 3
-------
1.6 Canadian Product Line Equipment........... 3
-------------------------------
SECTION 2 - REPRESENTATIONS AND WARRANTIES OF THE SELLER ... 4
2.1 Organization and Qualification ........... 4
------------------------------
2.2 Corporate Authorization .................. 4
-----------------------
2.3 Financial Data ........................... 4
--------------
2.4 No Material Adverse Change ............... 4
--------------------------
2.5 Compliance with Laws ..................... 4
--------------------
2.6 No Breach ................................ 5
---------
2.7 Actions and Proceedings .................. 6
-----------------------
2.8 Product Liability Claims ................. 6
------------------------
2.9 Sales Orders ............................. 6
------------
2.10 Inventory ................................ 6
---------
2.11 Tangible Property ........................ 6
-----------------
2.12 Intellectual Property .................... 7
---------------------
2.13 Title to Assets; Liens ................... 7
---------------------
2.14 Distributors and Other Customers ......... 7
--------------------------------
2.15 Manufacturing Documentation .............. 7
---------------------------
2.16 Brokerage ................................ 8
---------
2.17 Full Disclosure........................... 8
----------
SECTION 3 - REPRESENTATIONS AND WARRANTIES OF THE BUYER..... 8
3.1 Organization.............................. 8
------------
3.2 Corporate Authorization................... 8
-----------------------
3.3 Financial Statements...................... 8
--------------------
3.4 No Material Adverse Change................ 9
--------------------------
3.5 No Breach................................. 9
---------
3.6 Actions and Proceedings................... 9
-----------------------
3.7 Brokerage................................. 9
---------
SECTION 4 - COVENANTS AND AGREEMENTS........................ 9
4.1 Taxes..................................... 9
-----
4.2 Expenses.................................. 9
--------
4.3 Payment of Receivables.................... 10
----------------------
(i)
<PAGE> 3
4.4 Discharge of Liabilities.................. 10
------------------------
4.5 Further Assurances........................ 10
------------------
4.6 Noncompetition............................ 10
--------------
4.7 Inventory................................. 10
---------
4.8 Tangible Property......................... 11
-----------------
SECTION 5 - INDEMNIFICATION................................. 12
5.1 Obligation of Seller to Indemnify......... 12
---------------------------------
5.2 Obligation of the Buyer to Indemnify...... 12
------------------------------------
5.3 Limits on Indemnity....................... 12
-------------------
5.4 Procedure................................. 12
---------
5.5 Third Party Claims........................ 13
------------------
5.6 Limitation on Aggregate Liability......... 14
---------------------------------
5.7 Sharing of Data........................... 14
---------------
5.8 Use of the Seller's Markings.............. 14
----------------------------
SECTION 6 - MISCELLANEOUS................................... 15
6.1 Bulk Sales Law............................ 15
--------------
6.2 Publicity................................. 15
---------
6.3 Survival.................................. 15
--------
6.4 Notices................................... 15
-------
6.5 Entire Agreement.......................... 16
----------------
6.6 Amendment and Waiver; Rights Cumulative... 16
---------------------------------------
6.7 Governing Law............................. 17
-------------
6.8 Binding Effect; No Assignment............. 17
-----------------------------
6.9 Counterparts.............................. 17
------------
6.10 Headings.................................. 17
--------
(ii)
<PAGE> 4
EXHIBITS
--------
A - Form of Bill of Sale and Assignment and Assumption Agreement
B - Form of Supply and Transition Agreement
C - Form of Opinion of Seller's Counsel
D - Form of Opinion of Buyer's Counsel
E - Form of Canadian Bill of Sale
SCHEDULES
---------
I Products
1.1(b) Fixed Assets
2.4(a) Material Adverse Changes
2.5(a) Permits
2.8 Product Liability Claims
2.10 Inventory
2.12 Proprietary Rights Matters
2.12(b) Notices of Infringement of the Proprietary Rights
2.12(c) Trademarks, Trademark Applications and Registrations
2.14 Distributors and Other Customers
(iii)
<PAGE> 5
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT dated as of February 28, 1997 is between
Galileo Corporation (the "BUYER"), a Delaware corporation, with an address at
P.O. Box 550, Galileo Park, Sturbridge, Massachusetts 01566 and C.R. Bard, Inc.
(the "SELLER"), a New Jersey corporation, with an address at 730 Central Avenue,
Murray Hill, New Jersey 07974. The Seller has been conducting a business (the
"BUSINESS") involving the manufacture, marketing and sale of the products listed
in Schedule I hereto (the "PRODUCTS"), which are used by physicians in the
course of vaginal and rectal examinations, and the Buyer desires to acquire the
Business.
Accordingly, in consideration of the mutual representations, warranties,
covenants and agreements set forth below, the parties hereto agree as follows:
1 - SALE AND PURCHASE
1.1 PURCHASED ASSETS. Upon the terms and subject to the conditions of
this Agreement, the Seller agrees to sell, and the Buyer agrees to purchase, all
of the assets of the Business owned by the Seller and used or held for use or
sale exclusively in the Business, wherever located, other than the assets
described in Section 1.2 (the assets purchased by the Buyer hereunder being
referred to hereafter as the "PURCHASED ASSETS"), including without limitation
the following:
(a) All finished goods inventory existing on the date hereof
(the "INVENTORY").
(b) All machinery, equipment, molds, fixtures, tools and spare
parts, including without limitation the items listed on SCHEDULE 1.1(b) hereto.
(c) All documents and information with respect to the design,
development, manufacture, processing, marketing, testing or evaluation of the
Products; all manuals, manufacturer's or other warranties and diagrams relating
to the Products; all marketing artwork, negatives and film; all customer lists
and pricing information and material purchase costs and sources; provided,
however, that the Seller shall have no obligation to deliver (and the term
Purchased Assets shall not include) any of the items described in this Section
1.1(c) except to the extent they relate to current versions of the Products and
are presently available to the Seller. The Seller shall be entitled to deliver
copies of all of the foregoing documents, and need not deliver more than a
single copy of any document which exists in multiple copies.
(d) All intellectual property rights of, or licensed to, the
Seller and used in, or developed, acquired and currently held for use in, the
operation of the Business, including, without limitation, know-how, unpatented
inventions, copyrights and copyright applications, trademarks and trademark
applications, tradenames, marks and logos (whether or not registered) (excluding
the names and trademarks "Bard", "C.R. Bard", "Davol" and "Burnett Instruments"
and associated logos), plans, drawings, sketches, designs, process sheets,
manufacturing data and procedures, processes, trade secrets and specifications,
including all
<PAGE> 6
rights to the names "Sani-Spec," "Spec Light" and "Sani-Scope," or any variant
thereof and the goodwill relating thereto (collectively, the "Proprietary
Rights").
1.2 EXCLUDED ASSETS. Notwithstanding Section 1.1, the Purchased Assets
shall not include the following assets of the Seller or the assets described in
Section 1.2A related to the Spec Light Product (the "EXCLUDED ASSETS"):
(a) All cash and all accounts receivable outstanding on the
date hereof.
(b) All raw materials, work-in-progress and consumables.
(c) All sales orders and purchase orders and other agreements
existing on the date hereof.
(d) Any tangible or intangible assets, wherever located, which
are used or usable by the Seller in connection with the manufacture,
development, design or distribution of products other than the Products or
businesses other than the Business.
(e) Any patents, trade secrets, know-how, or other intangibles
(other than the name "Spec Light") relating to the design or manufacture of the
Spec Light product.
1.2A. SPEC LIGHT PRODUCT. The Seller has used the name "Spec Light" or
"Spec-Lite" since January 1970 but makes no claims of any kind with respect to
rights in the product marketed under the "Spec Light" name and is transferring
to the Buyer hereunder no rights of any kind with respect to such product other
than the Buyer's rights to the name "Spec Light". It purchases such product from
a vendor in Canada, and such vendor has claimed to own certain patent or other
intellectual property rights with respect to such product. The Buyer has agreed
to deal directly with said vendor in order to obtain further supplies of the
Spec Light product. Notwithstanding the foregoing, the Seller's inventory of the
Spec Light product shall be included as part of the Inventory. THE SELLER MAKES
NO REPRESENTATIONS OR WARRANTIES THAT THE MANUFACTURE, SALE OR DISTRIBUTION OF
THE SPEC LIGHT PRODUCT OR ANY PRODUCT THAT INCLUDES THE SPEC LIGHT, WILL NOT
INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF A THIRD PARTY.
1.3 NO ASSUMPTION OF LIABILITIES. By entering into this Agreement and
acquiring the Purchased Assets, the Buyer does not assume and shall have no
liability for any obligation or liability of the Seller of any kind, whether
known, unknown, direct or indirect, absolute or contingent, or mature or
unmatured.
1.4 PURCHASE PRICE. In exchange for the Purchased Assets, the Buyer is
paying to the Seller concurrently herewith an aggregate amount of $5,500,000
(the "Purchase Price") in cash by wire transfer. The parties will allocate the
Purchase Price among the Purchased Assets in a manner which complies with
Section 1060 of the Internal Revenue Code of 1986,
-2-
<PAGE> 7
as amended, within thirty (30) days. With respect to the allocation of a portion
of the Purchase Price to the Canadian Product Line Equipment, as defined in
Section 1.6 of this Agreement, such portion shall be deemed to be prepaid. The
parties will apply such allocation in connection with the preparation of their
respective federal, state and local tax returns and not voluntarily take any
position inconsistent therewith in any proceedings in connection therewith.
1.5 CLOSING. The closing of the sale and purchase of the Purchased
Assets hereunder (the "Closing") shall take place at the offices of Palmer &
Dodge LLP, One Beacon Street, Boston, Massachusetts concurrently with the
execution hereof. At the Closing, the Seller will deliver or cause to be
delivered to the Buyer (i) a Bill of Sale (under Kansas law), in the form
attached hereto as EXHIBIT A which shall be effective to vest in the Buyer good
title to all of the Purchased Assets (except for the Canadian Product Line
Equipment to be sold to the Buyer after the Closing, as described in Section
1.6), free and clear of all liens, restrictions and encumbrances, (ii) an
executed copy of the Supply and Transition Agreement (the "Supply Agreement") in
the form attached hereto as EXHIBIT B, and (iii) the opinion of Richard A.
Flink, Vice President and General Counsel of the Seller, dated as of the date
hereof in the form attached hereto as EXHIBIT C. The Seller will also deliver to
the Buyer at the Closing all documents and other information included in the
Purchased Assets, but the Seller may retain copies of such documents as may be
necessary to perform under the Supply Agreement. The Buyer will deliver the
opinion of Palmer & Dodge LLP, counsel to the Buyer, dated as of the date hereof
in the form attached hereto as EXHIBIT D. The Seller will retain the tangible
personal property required for performance of the Supply Agreement ("Retained
Property") and deliver the same to the Buyer in accordance with the Supply
Agreement or Section 1.6. The Buyer will take possession of all finished goods
Inventory held by third persons as of the date hereof and the Seller will
maintain possession of all finished goods Inventory and other Purchased Assets
in its possession for up to thirty (30) business days after the Closing in its
present locations without charge (but at the Buyer's risk of loss). Any items
other than Retained Property remaining in the Seller's possession after that
date may be placed in storage by the Seller at the Buyer's expense.
1.6 CANADIAN PRODUCT LINE EQUIPMENT. Upon completion of the
transactions contemplated by the parties under the Supply Agreement, the Seller
shall transfer to the Buyer title to all of the Product Line Equipment (as such
term is defined in the Supply Agreement) currently located at the Bard Canada,
Inc. ("Bard Canada") facilities (the "Canadian Product Line Equipment") and
deliver or cause to be delivered to the Buyer a Bill of Sale, in the form
attached hereto as EXHIBIT E, which shall be effective to vest in the Buyer good
title to all of the Canadian Product Line Equipment free and clear of all liens,
restrictions and encumbrances. Title to the Canadian Product Line Equipment
shall pass to the Buyer at Sturbridge, Massachusetts. The risk of loss with
respect to the Canadian Product Line Equipment shall pass to the Buyer as of the
date hereof.
-3-
<PAGE> 8
2 - REPRESENTATIONS AND WARRANTIES OF THE SELLER
The Seller represents and warrants to the Buyer as follows:
2.1 ORGANIZATION AND QUALIFICATION. The Seller is a corporation duly
organized, validly existing and in good standing under the laws of New Jersey
and has the corporate power and authority to own, lease and operate the
Purchased Assets, to carry on the Business as now conducted and to enter into
and perform this Agreement.
2.2 CORPORATE AUTHORIZATION. The execution, delivery and performance
of this Agreement have been duly authorized by the Board of Directors of the
Seller, and no other corporate action on the part of the Seller is required in
connection therewith. This Agreement has been duly executed and delivered by the
Seller and is the valid and binding obligation of the Seller enforceable in
accordance with its terms, subject, as to enforceability, to bankruptcy,
insolvency and other laws of general applicability relating to or affecting
creditors' rights and to general equity principles.
2.3 FINANCIAL DATA. Seller has previously provided to Buyer true and
correct copies of the United States and Canadian net and gross unit sales for
each Product for each of the three years ending December 31, 1996.
2.4 No Material Adverse Change. Since December 31, 1996,
---------------------------
(a) except as set forth on SCHEDULE 2.4(a) there has been no
material adverse change in the assets, properties, business, operations or
condition (financial or otherwise) of the Business, nor does the Seller know of
any such change that is threatened, nor has there been any damage, destruction
or loss materially and adversely affecting the Purchased Assets or the Business,
whether or not covered by insurance; and
(b) the Business has been conducted in all material respects in
the ordinary course and consistently with prior practices.
2.5 Compliance with Laws.
---------------------
(a) Set forth on SCHEDULE 2.5(a) are all of the licenses,
permits or franchises of any United States or Canadian federal, state,
provincial or local governmental or regulatory body, that are necessary for the
sale of the Products (collectively, "Permits"). The Seller and its subsidiaries
hold all Permits material to the conduct of the Business as presently conducted
and the use of the Purchased Assets. Such Permits are in full force and effect
and, except as set forth on SCHEDULE 2.5(a), such Permits will be transferred to
the Buyer as part of the Purchased Assets. To the knowledge of the Seller, no
material violations are or have been recorded with any governmental or
regulatory body in respect of any Permit and no proceeding is pending or
threatened to revoke or limit any Permit.
-4-
<PAGE> 9
(b) Neither the Seller nor any of its subsidiaries is in
violation of any order, judgment, injunction, award or decree binding upon it
and applicable to the Business. To the knowledge of the Seller, the Business is
not being conducted in violation in any material respect of any United States or
Canadian federal, state, provincial or local law, ordinance or regulation or any
other requirement of any United States or Canadian governmental or regulatory
body, court or arbitrator applicable to the Business or the Purchased Assets.
Neither the Seller nor any of its subsidiaries has received notice of, and there
has never been, any citation, fine or penalty imposed or asserted against the
Seller for any such violation or alleged violation.
(c) To the knowledge of the Seller, the Seller and its
subsidiaries have complied in all material respects with all applicable
requirements of the Food, Drug and Cosmetic Act, including the Safe Medical
Devices Act of 1990, and the regulations, policies and guidelines of the United
States Food and Drug Administration ("FDA") thereunder (collectively, the "FDA
ACTS AND REGULATIONS") and any similar laws, rules, regulations, policies and
guidelines of Canada (collectively, the "Canadian Regulations") relating to the
pre-market development, research, testing, production, distribution, sale and
marketing of the Products. Any necessary medical device pre-market notifications
and approval applications relating to the Products required by the FDA Acts and
Regulations or the Canadian Regulations relating to the Products have been filed
with the appropriate regulatory authority, and any necessary approvals or
concurrences relating to the Products have been obtained. Neither the Seller nor
any of its subsidiaries has applied for any investigational device exemption
relating to the Products.
(d) With respect to the Products, in the last three years,
there have been no (i) FDA or Canadian regulatory letters, notices of adverse
findings, warning letters or other correspondence in which the FDA or the
corresponding Canadian regulatory authority has stated or explicitly suggested
that the Seller or any of its subsidiaries has violated laws, regulations or
policies in its operation of the Business or (ii) recalls, market withdrawals,
FDA injunctions, seizures, criminal prosecutions, safety alerts, notifications
to medical practitioners or hospitals regarding safety risks or other matters,
or FDA or Canadian regulatory authority requests to repair Products or to refund
or reimburse on account of Product safety problems.
2.6 NO BREACH. The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby by Seller
do not (i) violate any provision of the charter or bylaws of the Seller, (ii)
violate or result in the breach of any of the terms or conditions of, result in
modification of the effect of, or otherwise give any other contracting party the
right to terminate, or constitute (or with notice or lapse of time or both
constitute) a default under, any material instrument, contract or other
agreement to which the Seller is a party or to which it or any of its assets or
properties is bound or subject, (iii) violate any order, judgment, injunction,
award or decree of any court, arbitrator or governmental or regulatory body
against, or binding upon, the Seller or upon its assets or properties, (iv)
violate any United States or Canadian law, ordinance or regulation applicable to
the Seller, (v) violate any Permit, (vi) require the approval or consent of any
United States or Canadian
-5-
<PAGE> 10
federal, state, provincial or other governmental or regulatory body or the
approval or consent of any other person or (vii) result in the creation of any
lien or other encumbrance on the Purchased Assets.
2.7 ACTION AND PROCEEDINGS. There are no outstanding orders,
judgments, injunctions, awards or decrees of any United States or Canadian
court, governmental or regulatory body or arbitration tribunal against the
Seller or its subsidiaries and applicable to the Business or the Purchased
Assets. Except as set forth on SCHEDULE 2.8, there are no actions, suits or
claims or legal, administrative or arbitral proceedings or, to the knowledge of
the Seller, investigations affecting the Business uniquely (whether or not the
defense thereof or liabilities in respect thereof are covered by insurance)
pending or, to the knowledge of the Seller, threatened against the Seller that
would affect the Business or the Purchased Assets. To the knowledge of the
Seller, there is no fact, event or circumstance (other than facts, events and
circumstances applicable both to the Business and other businesses similar to
the Business) that could reasonably be expected to give rise to any suit,
action, claim, investigation or proceeding that individually or in the aggregate
could have a material adverse effect upon the transactions contemplated hereby
or upon the Business or the Purchased Assets.
2.8 PRODUCT LIABILITY CLAIMS. Except as set forth on SCHEDULE 2.8
hereto, since January 1, 1992, no Product Liability Claim, as defined hereafter,
has been made or, to the knowledge of Seller, threatened against the Seller or
any of its subsidiaries with respect to the Products. The Business has not
experienced Product recall or warranty claims in excess of 5% of the aggregate
gross sales of the Business for any of the past five years. Seller has provided
to Buyer summaries of all customer complaints and all recall information
relating to the Products for the past five years. For purposes of this
Agreement, "PRODUCT LIABILITY CLAIM" means any obligation, claim or liability
under breach of warranty, tort, contract or any other theory caused by or
resulting, directly or indirectly, from the design, manufacture, assembly, sale
or servicing of any Product.
2.9 SALES ORDERS. There are no sales orders or commitments and no
commission or rebate arrangements relating to the Business that will be binding
upon the Buyer by operation of law or otherwise, as of the date hereof.
2.10 INVENTORY. SCHEDULE 2.10 hereto lists all raw material and
finished goods Inventory of the Seller's United States and Canadian operations
as of December 31, 1996 and January 31, 1997 and all finished goods Inventory of
the Seller's United States operations as of February 26, 1997. The Buyer
confirms its understanding that the exact quantity of Inventory on hand will
vary from the amount listed in SCHEDULE 2.10. The Business is not under any
obligation with respect to the return of inventory or products in the possession
of customers or others that would have a material adverse effect on the
Business.
2.11 TANGIBLE PROPERTY. The Buyer confirms that it has had sufficient
opportunity to inspect and assess the tangible Purchased Assets related to the
Seller's United States and Canadian operations, including all Inventory,
machinery, equipment, molds, fixtures, tools
-6-
<PAGE> 11
and spare parts to be purchased by the Buyer hereunder. Seller confirms that the
tangible Purchased Assets have been maintained in the ordinary course since the
date last examined by the Buyer.
2.12 INTELLECTUAL PROPERTY. The provisions of this Section 2.12 are
qualified and limited by reference to Section 1.2A and SCHEDULE 2.12.
(a) The Seller owns or has the right to use all of the
Proprietary Rights.
(b) Other than as set forth on SCHEDULE 2.12(b), the Seller has
not received any notices of infringement by the Seller or any of its
subsidiaries of any proprietary rights of others in connection with its
operation of the Business or its use of the Proprietary Rights, and, to the
knowledge of the Seller, none of the present activities of the Business and none
of the Products infringe on any proprietary rights of others. The Seller is not
aware of any infringement or violation by others of the Proprietary Rights of
the Seller or its subsidiaries.
(c) All trademarks, trademark applications and registrations or
trade names (or applications therefor) which are to be purchased by the Buyer
hereunder are listed in SCHEDULE 2.12(c) hereto. The Seller does not own or
license any patents in connection with the conduct of the Business.
(d) The Proprietary Rights sold and transferred to the Buyer
hereunder are sufficient to carry on the operation of the Business as presently
conducted.
2.13 TITLE TO ASSETS; LIENS. The Seller has, and in the case of the
Canadian Product Line Equipment will have at the time of transfer under Section
1.6, good title to (or in the case of the Proprietary Rights, the right to use)
all of the Purchased Assets, free and clear of any claim, lien or other
encumbrance, except for liens or other encumbrances securing the claims of
materialmen, carriers, landlords and like persons, all of which are not yet due
and payable. Upon delivery of and payment for the Purchased Assets as herein
provided, the Buyer will acquire all of the Seller's right, title and interest
thereto, free and clear of any claim, lien or other encumbrance.
2.14 DISTRIBUTORS AND OTHER CUSTOMERS. SCHEDULE 2.14 hereto sets forth
the United States and Canadian distributors and other customers of Products for
the twelve months ended December 31, 1996.
2.15 MANUFACTURING DOCUMENTATION. True and substantially complete
copies of any and all specifications, process descriptions and other technical
data (including chemical formulations, design specifications and manufacturing
protocols) used by Seller and Bard Canada for the manufacture of the Products
(the "Manufacturing Documentation") are being furnished to the Buyer at the
Closing.
-7-
<PAGE> 12
2.16 BROKERAGE. No broker, finder, agent or similar intermediary has
acted on behalf of the Seller in connection with this Agreement or the
transactions contemplated hereby, and there are no brokerage commissions,
finders fees or similar fees or commissions payable in connection therewith
based on any agreement, arrangement or understanding with the Seller.
2.17 Full Disclosure. The representations, warranties and statements of
the Seller contained in this Agreement do not contain any untrue statement of a
material fact, and, taken as a whole, do not omit to state any material fact
necessary to make such representations, warranties and statements, in light of
the circumstances under which they are made, not misleading. The Buyer confirms
that it has had access to the assets, properties and operations of the Business
as reasonably necessary in connection with its investigation of the Business and
verification of the representations and warranties set forth in Section 2 of
this Agreement. Notwithstanding the foregoing, no investigation by the Buyer
shall diminish or obviate any of the representations, warranties, covenants or
agreements of the Seller under this Agreement.
3 - REPRESENTATIONS AND WARRANTIES OF THE BUYER
The Buyer represents and warrants to the Seller as follows:
3.1 ORGANIZATION. The Buyer is duly organized, validly existing and in
good standing under the laws of Delaware, and has the corporate power and
authority to own, lease and operate its assets, properties and business and to
carry on its business as now being conducted and to enter into and perform this
Agreement.
3.2 CORPORATE AUTHORIZATION. The execution, delivery and performance
of this Agreement have been duly authorized by the Board of Directors of the
Buyer, and no other corporate action on the part of the Buyer is required in
connection therewith. This Agreement has been duly executed and delivered by the
Buyer and is the valid and binding obligation of the Buyer enforceable in
accordance with its terms, subject, as to enforceability, to bankruptcy,
insolvency and other laws of general applicability relating to or affecting
creditors' rights and to general equity principles.
3.3 FINANCIAL STATEMENTS. The audited consolidated balance sheets of
the Buyer as at September 30, 1996 and 1995 and the related consolidated
statements of operations and cash flows for the years then ended, which have
previously been delivered to the Seller, fairly present in all material respects
the financial condition and results of operations of the Buyer as at such dates
and for the years then ended in accordance with generally accepted accounting
principles ("GAAP") consistently applied throughout the periods covered. The
unaudited consolidated balance sheet of the Buyer as at December 31, 1996, and
the related statements of operations and cash flows for the quarter then ended,
previously delivered to the Seller, fairly present in all material respects the
financial condition of the Buyer as at such date, and for the quarter then
ended, in accordance with GAAP consistently applied throughout the period
covered, subject to normal year-end adjustments.
-8-
<PAGE> 13
3.4 NO MATERIAL ADVERSE CHANGE. Since December 31, 1996, other than as
disclosed on the Buyer's Quarterly Report on Form 10-Q for the fiscal quarter
ended December 31, 1996, as filed with the Securities and Exchange Commission,
there has been no material adverse change in the assets, properties, business,
operations or condition (financial or otherwise) of the Buyer.
3.5 NO BREACH. The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby do not
(i) violate any provision of the charter or bylaws of the Buyer, (ii) violate or
result in the breach of any of the terms or conditions of, result in
modification of the effect of, or otherwise give any other contracting party the
right to terminate, or constitute (or with notice or lapse of time or both
constitute) a default under, any material instrument, contract or other
agreement to which the Buyer is a party or to which it or any of its assets or
properties is bound or subject, (iii) violate any order, judgment, injunction,
award or decree of any court, arbitrator or governmental or regulatory body
against, or binding upon, the Buyer or upon its assets or properties, (iv)
violate any law, ordinance or regulation of any jurisdiction applicable to the
Buyer or (v) require the approval or consent of any foreign, federal, state,
local or other governmental or regulatory body or the approval or consent of any
other person.
3.6 ACTIONS AND PROCEEDINGS. There are no actions, suits or claims,
legal, administrative or arbitral proceedings pending or, to the knowledge of
the Buyer, threatened against the Buyer that individually or in the aggregate
could have a material adverse effect upon the transactions contemplated hereby.
To the knowledge of the Buyer, there is no fact, event or circumstance that may
give rise to any suit, action, claim, investigation or proceeding that
individually or in the aggregate could have a material adverse effect upon the
transactions contemplated hereby.
3.7 BROKERAGE. No broker, finder, agent or similar intermediary has
acted on behalf of the Buyer in connection with this Agreement or the
transactions contemplated hereby, and there are no brokerage commissions,
finders' fees or similar fees or commissions payable in connection therewith
based on any agreement, arrangement or understanding with the Buyer.
4 - COVENANTS AND AGREEMENTS
The parties covenant and agree as follows:
4.1 TAXES. All sales, use and transfer and other taxes incurred in
connection with the sale of the Purchased Assets to the Buyer hereunder shall be
paid by the party on which such taxes are assessed under applicable law.
4.2 EXPENSES. The Buyer and the Seller shall bear their respective
expenses incurred in connection with the preparation, execution and performance
of this Agreement and
-9-
<PAGE> 14
the transactions contemplated hereby, including without limitation, all fees and
expenses of agents, representatives, counsel and accountants.
4.3 PAYMENT OF RECEIVABLES. Subsequent to the date hereof, each party
will promptly deliver to the other any cash or other property mistakenly
delivered to such party, by persons unaware of the Buyer's purchase of the
Business.
4.4 DISCHARGE OF LIABILITIES. Seller will discharge all obligations of
the Seller and its subsidiaries affecting or relating to the Business or the
Purchased Assets on or before the maturity thereof, other than obligations
expressly assumed by the Buyer hereunder. The Buyer shall assume, pay and
perform when due all obligations arising after the date hereof in connection
with its operation of the Business.
4.5 FURTHER ASSURANCES. Each of the parties will execute such
documents, further instruments of transfer and assignment and other papers and
take such further actions as may be reasonably required or desirable to carry
out the provisions hereof and the transactions contemplated hereby, including
the registration of any trademarks by the Buyer. The Seller will provide at its
expense such information and evidence as the Buyer may reasonably request to
establish Seller's use of any of the names included in the Proprietary Rights.
4.6 NONCOMPETITION. In order to induce the Buyer to purchase the
Business and the Purchased Assets hereunder and to assure to the Buyer the
benefits thereof, the Seller will not for a period of five years following the
date hereof, directly or indirectly, develop, manufacture, sell, or otherwise
provide any products substantially similar to, or directly or indirectly
competitive with, the Business or any Product, including the provision of such
products under any sales orders or pricing arrangements existing prior to the
date hereof. Notwithstanding the foregoing, this Section shall not preclude (X)
the Seller from acquiring a business or entity if less than 10% of the revenues
(determined as of the fiscal year preceding such acquisition) and less than 10%
of the assets (determined as of the closing of such acquisition) (together, the
"Revenue and Asset Limitations") of such acquired business or entity were
derived from activities which would be competing activities within the terms of
this section (the "Competing Assets"), or (Y) the Seller or any division or
subsidiary of Seller from being acquired by an entity which, directly or
indirectly, engages in a business or conducts business in a manner, which
competes with the Business or any Product or the conduct of the Business.
Notwithstanding the foregoing, the Seller may acquire a business or entity with
Competing Assets in excess of the Revenue and Asset Limitations as long as such
Competing Assets are disposed of within one year of such acquisition. The Seller
acknowledges that the remedy at law for any breach of the foregoing covenant
will be inadequate and that the Buyer shall, in addition to whatever other
remedies it may have at law or in equity, be entitled to injunctive relief
without the necessity of proving actual damages or posting a bond.
4.7 INVENTORY. (a) Finished goods Inventory purchased by the Buyer
shall conform to the Manufacturing Documentation and shall be free from defects
in material and
-10-
<PAGE> 15
workmanship as of the Closing. The Buyer shall have a period of 45 days from the
date hereof ("Acceptance Period") to reject any finished goods Inventory for
nonconformity with the Manufacturing Documentation and for defects in material
and workmanship. During such Acceptance Period, upon a good faith rejection of
any finished goods Inventory or any portion thereof, Buyer shall have an
absolute right of refund in an amount equal to the price payable by the Buyer
for the corresponding Product under the Supply Agreement. After the end of the
Acceptance Period, no Inventory may be rejected and the Seller shall have no
obligation to honor claims for breach of the foregoing warranty unless (X) the
Buyer shall have asserted a claim of non-conformity to Manufacturing
Documentation or defect in material or workmanship before the date which is five
months after the end of the Acceptance Period and (Y) the Buyer shall have
demonstrated that the alleged nonconformity of the allegedly-defective Inventory
was caused by the Seller's or Bard Canada's failure to manufacture such Products
in accordance with the Manufacturing Documentation or by defects in material or
workmanship ("Fault of Seller") and not solely by any other cause, including
improper storage, damage in transit, or other mishandling by the Buyer or any
selected carrier. In the event that the Seller disagrees with the Buyer's claim
that a Product defect was caused by the Fault of Seller, it shall submit such
question to the Special Arbitration provided for in Section 5.3 of the Supply
Agreement. The decision of the Special Arbitrator shall be final and binding as
to the extent to which the Product defect was caused by the Fault of Seller. If
the Special Arbitrator determines that the Buyer has proven that the
nonconformity was caused by the Fault of Seller, the Seller or, if applicable,
Bard Canada, shall issue a credit or refund to the Buyer, in the Buyer's
discretion, in an amount equal to the price payable by the Buyer for the
corresponding Product under the Supply Agreement.
(b) The warranty contained in this Section 4.7 does not
include, nor does the Seller or Bard Canada assume responsibility for, defects
or damage caused by alterations, misuse, improper storage, or damage in transit
or shipping. EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN THIS AGREEMENT, THE
WARRANTIES MADE IN THIS SECTION ARE THE SOLE WARRANTIES MADE BY THE SELLER WITH
RESPECT TO THE PRODUCTS AND ARE MADE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING, BY WAY OF EXAMPLE AND NOT LIMITATION WARRANTIES OF DESIGN,
MERCHANTABILITY, AND OF FITNESS FOR A PARTICULAR PURPOSE.
4.8 TANGIBLE PROPERTY. Except as otherwise provided in this Agreement,
the machinery, equipment, molds, fixtures, tools and spare parts to be purchased
by the Buyer hereunder are being sold AS IS, WHERE IS, WITHOUT ANY
REPRESENTATION OR WARRANTY OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED,
INCLUDING, BY WAY OF EXAMPLE AND NOT LIMITATION, WARRANTIES OF DESIGN,
MERCHANTABILITY, AND OF FITNESS FOR A PARTICULAR PURPOSE. Any costs resulting
from damage to the tangible Purchased Assets incurred in shipping such Purchased
Assets to the Buyer shall be borne by the Buyer.
-11-
<PAGE> 16
5 - INDEMNIFICATION
5.1 OBLIGATION OF SELLER TO INDEMNIFY. The Seller will indemnify and
hold harmless the Buyer (and its directors, officers, employees, agents,
affiliates and assigns) from and against all losses, liabilities, damages,
deficiencies, costs or expenses, including interest and penalties imposed or
assessed by any judicial or administrative body and reasonable attorneys' fees,
whether or not arising out of third-party claims and including all amounts paid
in investigation, defense or settlement of the foregoing ("LOSSES") based upon,
arising out of or otherwise in respect of (i) any inaccuracy in or breach of any
representation, warranty, covenant or agreement of the Seller contained in this
Agreement or in any certificate delivered pursuant hereto, (ii) the conduct of
the Business by the Seller or any of its subsidiaries prior to the date hereof,
except for any liability expressly assumed by the Buyer hereunder, or (iii) any
Product Liability claim made on or after the date hereof in connection with the
manufacture, sale or use of any of the Products manufactured by the Seller or
Bard Canada prior to the date hereof (to the extent that the defect which gave
rise to such claim is determined to have been caused by the Fault of Seller).
5.2 OBLIGATION OF THE BUYER TO INDEMNIFY. The Buyer will indemnify and
hold harmless the Seller (and its directors, officers, employees, agents,
affiliates and assigns) from and against any Losses based upon, arising out of
or otherwise in respect of (i) any inaccuracy in or breach of any
representation, warranty, covenant or agreement of the Buyer contained in this
Agreement or in any certificate delivered pursuant hereto, (ii) the conduct of
the Business by the Buyer after the date hereof, or (iii) any Product Liability
claim made on or after the date hereof in connection with the manufacture, sale
or use of any Product (other than Products manufactured by the Seller) after the
date hereof. With respect to a product liability claim arising from a Product
manufactured by the Seller or Bard Canada but sold by the Buyer, the Buyer will
indemnify and hold harmless the Seller or Bard Canada from and against any
resulting Losses, except to the extent that the defect which gave rise to such
claim is determined to have been caused by the Fault of Seller. The Buyer will
indemnify the Seller or Bard Canada against all Losses based upon, arising out
of or otherwise in respect of the improper storage of the finished goods
Inventory or the shipping of such Inventory.
5.3 LIMITS ON INDEMNITY. The indemnification provided for in this
Agreement shall not apply unless and until the aggregate Losses for which a
party entitled to indemnification hereunder (the "Indemnified Party") seeks
indemnification, exclusive of legal fees, exceeds $25,000, in which case
indemnification will include all losses, provided that there shall be no
limitation on the amount recoverable with respect to Inventory by the Buyer
under Section 4.7.
5.4 PROCEDURE. If an Indemnified Party believes that it has suffered
or incurred (or has knowledge of facts and circumstances which lead it to
believe that it can reasonably expect to suffer or incur) any Losses, such
Indemnified Party shall notify the other party (the "Indemnifying Party")
promptly in writing, describing the Losses, the amount thereof, if known, and
(if appropriate) the method of computation of such Losses, all with reasonable
specificity and containing a reference to the applicable provisions of this
Agreement in respect
-12-
<PAGE> 17
of which such Losses have occurred (or is reasonably expected to occur),
provided however, that the failure to so notify shall not affect the obligations
of the Indemnifying Party to provide indemnification except to the extent that
the Indemnifying Party has been materially prejudiced by such failure to give
reasonably prompt notice.
5.5 THIRD PARTY CLAIMS. The following provisions shall apply to claims
for indemnification hereunder resulting from or in connection with claims or
legal proceedings by a third party:
5.5.1 In the event of any such claim for indemnification
hereunder resulting from or in connection with any claim or legal proceedings by
a third party, the notice to the Indemnifying Party shall specify, if known, the
amount or an estimate of the amount of the liability arising therefrom and a
description of the third party claim. The Indemnified Party shall not settle or
compromise any claim by a third party for which it is entitled to
indemnification hereunder without the prior written consent of the Indemnifying
Party (which consent shall not be unreasonably withheld or delayed) unless suit
shall have been instituted against it and the Indemnifying Party shall not have
taken control of such suit after notification thereof as provided in this
Agreement. The Indemnified Party shall cooperate fully with the Indemnifying
Party in the conduct of any such defense, contest or action.
5.5.2 In the event the Indemnifying Party shall be obligated to
pay expenses in connection with any claim giving rise to indemnity hereunder
resulting from or arising out of any claim or legal proceeding by a person which
is not a party to this Agreement, the Indemnifying Party shall be entitled to
participate in such proceeding and, to the extent it shall wish, to assume the
defense of such proceeding, with counsel chosen by the Indemnifying Party and
approved by the Indemnified Party, which approval shall not be unreasonably
withheld. Upon the delivery to the Indemnified Party of written notice of its
election to assume such defense, approval of such counsel by the Indemnified
Party and retention of such counsel by the Indemnifying Party, the Indemnifying
Party will not be liable to the Indemnified Party under this Agreement for any
fees of counsel or other expenses subsequently incurred by the Indemnified Party
in connection with the defense of the same proceeding, except for reasonable
fees and expenses incurred by the Indemnified Party as a consequence of the
Indemnified Party's obligation to cooperate with the Indemnifying Party in
defense of such matters. The Indemnified Party shall have the right to employ
its own counsel in any such proceeding at the expense of the Indemnifying Party
if (i) the employment of counsel by the Indemnified Party has been previously
authorized by the Indemnifying Party, (ii) the Indemnified Party shall have
reasonably concluded that there may be a conflict of interest between the
Indemnifying Party and the Indemnified Party in the conduct of such defense or
that such counsel and the Indemnified Party have fundamental and material
disagreements as to the proper method of managing the litigation, or (iii) the
Indemnifying Party shall not have employed counsel approved by the Indemnified
Party to assume the defense of such proceeding. Notwithstanding the foregoing,
the Indemnified Party shall have the right to employ its own counsel in any such
proceeding at its own expense.
-13-
<PAGE> 18
5.5.3 If the Indemnifying Party does not assume the defense of
any such claim or litigation resulting therefrom within thirty (30) days after
the date the Indemnified Party makes a written request for indemnification
hereunder, (i) the Indemnified Party may defend against such claim or
litigation, in such manner as it may deem appropriate, including, but not
limited to, settling such claim or litigation, after giving notice to the
Indemnifying Party, on such terms as the Indemnified Party may deem appropriate,
and (ii) the Indemnifying Party shall be entitled to participate in (but not
control) the defense of such action, with its own counsel and at its own
expense. If the Indemnifying Party thereafter seeks to question the manner in
which the Indemnified Party defended such third party claim or the amount or
nature of any such settlement, the Indemnifying Party shall have the burden to
prove by a preponderance of the evidence that the Indemnified Party did not
defend or settle such third party claim in a reasonably prudent manner.
5.6 LIMITATION ON AGGREGATE LIABILITY. Notwithstanding any other
provision of this Agreement, the maximum liability of the Indemnifying Party to
the Indemnified Party (whether based on contract, tort, indemnification or other
theory) with respect to any matters other than Product Liability Claims shall
not exceed the Purchase Price.
5.7 SHARING OF DATA. The Seller shall have the right for a period of
six years following the date hereof to have reasonable access to such books,
records and accounts, including financial and tax information, correspondence,
production records, and other similar information as are transferred to the
Buyer pursuant to the terms of this Agreement for the limited purposes of
concluding its involvement in the Business prior to the date hereof, complying
with its obligations under applicable securities, tax, environmental, employment
or other laws and regulations, and defending against a claim or litigation. The
Buyer shall have the right for a period of six years following the date hereof
to have reasonable access to such books, records and accounts, including
financial and tax information, correspondence, production records, manufacturing
and design documentation, and other information for the limited purposes of
complying with its obligations under applicable securities, tax, environmental,
employment or other laws and regulations and defending against a claim or
litigation, and as otherwise may reasonably be required by Buyer in its conduct
of the Business. Notwithstanding the foregoing, this section shall not create
any obligation on the part of the Buyer or the Seller to protect or retain
records which would otherwise be disposed of under the party's normal records
retention policy.
5.8 USE OF THE SELLER'S MARKINGS. For a period of one year following
the date hereof, or until the Buyer exhausts Inventory items consisting of
printed or molded materials containing any name, symbol or trademark owned by or
licensed to the Seller or any affiliate of the Seller and not included in the
Purchased Assets (collectively, "Seller's Markings"), whichever shall earlier
occur, the Seller hereby grants to the Buyer a limited, non-exclusive right to
use of the Seller's Markings as they appear on printed or molded Purchased
Assets existing as of the date hereof. The Seller reserves all rights in and to
the Seller's Markings and all goodwill associated therewith, whether or not
arising out of this Agreement. The Buyer shall not use the Seller's Markings in
any manner that may diminish the value thereof.
-14-
<PAGE> 19
All use of the Seller's Markings and all goodwill associated therewith shall
inure to the benefit of the Seller. Without limitation of the foregoing, in the
event any claim is made against the Seller solely by reason of the
identification of Products sold by the Buyer as the Seller's products because of
the rights granted to the Buyer under this Section, the Buyer shall indemnify,
defend, and hold the Seller, or, if applicable, Bard Canada, harmless from any
liability arising with respect to such claim in accordance with the provisions
of Section 5 hereof.
6 - MISCELLANEOUS
6.1 BULK SALES LAW. The Buyer waives compliance by Seller with the
obligations imposed as a result of the transactions contemplated by this
Agreement under any applicable bulk sales laws. The Seller will indemnify and
hold Buyer harmless from any liability, loss, claim and expense arising from the
failure to comply with such obligations.
6.2 PUBLICITY. No publicity release or announcement concerning this
Agreement or the transactions contemplated hereby shall be made without advance
approval thereof by the Seller and the Buyer, except as otherwise required by
law as advised by counsel to a party with prior notice to the other party.
6.3 SURVIVAL. Notwithstanding the right of a party to fully
investigate the affairs of the other party and notwithstanding any knowledge of
facts determined or determinable by such party pursuant to such investigation or
right of investigation, each party has the right to rely fully upon the
representations, warranties, covenants and agreements of the other party in this
Agreement or in any certificate, financial statement or other document delivered
by any party pursuant hereto. All such representations, warranties, covenants
and agreements shall survive the execution and delivery hereof for a three year
period beginning on the date hereof.
6.4 NOTICES. Any notice or other communication required or permitted
hereunder shall be in writing and shall be deemed given when delivered in
person, by overnight courier, by facsimile transmission (with receipt confirmed
by telephone or automatic transmission report) or two business days after being
sent by registered or certified mail, postage prepaid, as follows:
(i) if to the Buyer, to:
Galileo Corporation
P.O. Box 550
Galileo Park
Sturbridge, MA 01566
Fax: (508) 347-2270
Attention: Josef W. Rokus, Vice President, Corporate
Development
-15-
<PAGE> 20
with a copy to:
David R. Pokross, Jr., Esq.
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108
Fax: (617) 227-4420
(ii) if to the Seller, to:
C.R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974
Fax: (908) 277-8363
Attention: Daniel J. Doyle, Director Corporate
Planning and Development
with a copy to:
Peter W. Coogan, Esq.
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109
Fax: (617) 832-7000
Any party may by notice given in accordance with this section to the other
parties designate another address or person for receipt of notices hereunder.
6.5 ENTIRE AGREEMENT. This Agreement and the other documents executed
in connection with the consummation of the transactions contemplated hereby
contain the entire agreement between the parties with respect to the subject
matter hereof, and supersede all prior agreements, written or oral, with respect
thereto.
6.6 AMENDMENT AND WAIVER; RIGHTS CUMULATIVE. This Agreement may be
amended, and the terms hereof may be waived, only by a written instrument
signed by the parties or, in the case of a waiver, by the party waiving
compliance. No delay on the part of any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof nor shall any waiver on
the part of any party of any such right, power or privilege, nor any single or
partial exercise of any such right, power or privilege, preclude any further
exercise thereof or the exercise of any other such right, power or privilege.
The rights and
-16-
<PAGE> 21
remedies herein provided are cumulative and are not exclusive of any rights or
remedies that any party may otherwise have at law or in equity.
6.7 GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the Commonwealth of Massachusetts, without regard to
its conflict of laws provisions.
6.8 BINDING EFFECT; NO ASSIGNMENT. This Agreement shall be binding
upon and inure to the benefit of the parties and their respective successors and
permitted assigns. Buyer and Seller may not assign or delegate any of their
rights or obligations hereunder.
6.9 COUNTERPARTS. This Agreement may be executed in separate
counterparts, each of which shall be deemed an original, but all which together
shall constitute one and the same instrument. Each counterpart may consist of a
number of copies hereof each signed by less than all but together signed by all
of the parties hereto.
6.10 HEADINGS. The headings in this Agreement are for reference only,
and shall not affect the interpretation of this Agreement.
-17-
<PAGE> 22
IN WITNESS WHEREOF, the parties have executed this Agreement under seal
as of the date first above written.
GALILEO CORPORATION
By: /s/ William T. Hanley
------------------------------------
Title: President and Chief Executive
Officer
C.R. BARD, INC.
By: /s/ Richard A. Flink
-----------------------------------
Title: Vice President
-18-
<PAGE> 1
Exhibit No. 99.1
- -------------------------------------------------------------------------------
GALILEO NEWS
- -------------------------------------------------------------------------------
===============================================================================
FROM: DAVID MANDY JOHN CHUHRAN, MEDIA CONSULTANT
PORTER, LE VAY & ROSE, INC. PORTER, LE VAY & ROSE, INC.
(212) 564-4700 (212) 564-4700
COMPANY GREGORY RIEDEL, CHIEF FINANCIAL OFFICER
CONTACTS: GALILEO CORP.
(508) 347-4222
KIP SPEYER, PRESIDENT BOB RABINER, GENERAL MANAGER
LEISEGANG MEDICAL MEDICAL PRODUCTS GROUP
(561) 994-0202 (508) 347-4232
FOR IMMEDIATE RELEASE
GALILEO ACQUIRES SANI-SPEC(TM) PRODUCT LINE FROM C.R. BARD, INC.
STURBRIDGE, MA, MARCH 3 -- Galileo Corporation (NASDAQ, NM:GAEO), today
announced the acquisition of the Sani-Spec(TM) product line from C.R. Bard, Inc.
The Sani-Spec product line includes a comprehensive suite of women's
health-related products used by OB/GYN physicians, clinics and hospitals
including Sani-Spec(TM) single-use vaginal speculums, Sani-Scope(TM) anoscopes,
Spec Light(TM) speculum lights and Pap Smear kits. The product line is marketed
through a nationwide network of approximately 80 dealers and has been a market
leader for over 20 years. Last year's revenues were in excess of $4.0 million,
representing over 40% of the domestic market.
-more-
Galileo Corporation Galileo Park P.O. Box 550 Sturbridge, MA 01566 USA
TEL. (508) 347-9191 FAX (508) 347-3849
World Wide Web Site: http://www.galileocorp.com
<PAGE> 2
-2-
William T. Hanley, President and Chief Executive Officer, said, "We are
very pleased to be adding the most frequently used instruments in the
gynecologist's office to our growing portfolio of women's health products. The
addition of these products and their related distribution channel represents an
integral part of our continuing strategy to increase our presence in women's
health and expand distribution for all our medical products, including those
marketed by Leisegang Medical, our wholly-owned subsidiary. We anticipate that
this acquisition will be immediately accretive to earnings."
Kip Speyer, President, Leisegang Medical, stated, "This acquisition
expands the distribution channel for all our medical products and provides a
unique opportunity to enhance customer service by combining the Sani-Spec
products with our extensive line of colposcopes, ultrasound devices, rigid and
flexible hysterscopes, fetal monitors and endoscopes."
Galileo purchased the product line for $5.5 million, and the acquisition
will be accounted for as a purchase. Manufacturing will relocate to the
Company's principal facility in Sturbridge, Massachusetts.
Galileo Corporation develops, manufactures, and markets products based on
its core fiberoptics and electro-optics technologies for applications in medical
products and instruments, telecommunications products, analytical detector
instruments, and office equipment. Galileo markets its products to OEMs, through
marketing partners, and direct to end-users. Leisegang Medical, a wholly-owned
subsidiary, develops, manufactures, and markets women's health-related medical
products.
#####
1997
